Diagnostics Pipeline: Expanded DPYD Test Anticipated to Make Chemotherapy Safer
Labcorp’s new genotyping test can identify gene variants that may make standard oncologic treatment deadly for some
Already a member? Log in here
Author Information
Ron Shinkman
Ron Shinkman is a veteran journalist and editor with more than 20 years of experience in the healthcare business realm. He served as Los Angeles bureau chief of Modern Healthcare and also wrote for the Los Angeles and Orange County Business Journals.
Posts by the Author
FDA Watch: Natera, Valar Labs Receive FDA Clearances for Bladder Cancer Tests
Natera’s assay focuses on the need for adjuvant therapy, while Valar’s test stratifies risk of recurrence
Already a member? Log in here
Dx Deals: QuidelOrtho Closes LEX Diagnostics Acquisition
Deal could prove a boost to the company, which has struggled since 2023
Already a member? Log in here
CMS-lcaCMS-lirCMS-nirEssentialFDA-lirFDA-nirLab Industry AdvisorReimbursement-lcaReimbursement-lirReimbursement-nirRon Shinkman
FDA Watch: New RAPID Coverage Pathway Would Enable Some Lab Tests to Pursue Clearance and Medicare Coverage Simultaneously
FDA-CMS collaboration aims to accelerate Medicare coverage determinations of certain medical devices
Already a member? Log in here
Dx Deals: Blackstone, TPG Take Hologic Private in $18.5 Billion Deal
Hologic has been on the vanguard of developing and distributing tests focusing on women’s health
Already a member? Log in here
Diagnostics Pipeline: To Gain Insight into Haystack MRD Test, Quest Works with City of Hope
New liquid biopsy assay will be used in conjunction with 500 cancer patients currently enrolled in clinical trials
Already a member? Log in here
Quest Diagnostics Launches Consumer-Facing AI on Its App and Portal
The company’s patients can use AI to look at trends going back five years
Already a member? Log in here
Thermo Fisher Scientific Debuts Pharmacogenetic Test to Improve Transplant Safety
Proper dosing helps prevent potential side effects such as developing diabetes and kidney damage
Already a member? Log in here
Dx Deals: Abbott Closes Exact Sciences Acquisition, Takes Control of Cologuard Franchise
Biotech giant purchased the company for $21 billion, one of the largest deals in clinical lab history
Already a member? Log in here
FDA Watch: MeMed and NG Biotech Receive FDA Breakthrough Device Designations for Rapid Infection Tests
In both cases, the diagnostic tests report results back within 15 minutes
Already a member? Log in here
